HMGCR and breast cancer: These findings suggested that there were possible mechanism-specific protective effects of statins (targeting HMG-CoA reductase) and ezetimibe (targeting NPC1L1) on breast cancer, whereas PCSK9 inhibitors might have protective effect on prostate cancer.